[Consequences of unexpected drug effects, beginning with contergan studies by pediatrists].
D000014:Abnormalities, Drug-Induced; D000170:Acrodynia / Q000139:chemically induced; D001424:Bacterial Infections / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D002701:Chloramphenicol / Q000009:adverse effects; D004480:Ectromelia / Q000139:chemically induced; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008431:Maternal-Fetal Exchange; D008628:Mercury / Q000009:adverse effects; D011247:Pregnancy; D012279:Rickets / Q000188:drug therapy; D018805:Sepsis / Q000188:drug therapy; D013792:Thalidomide / Q000009:adverse effects*; D014807:Vitamin D / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D014807:Vitamin D; D013792:Thalidomide; D002701:Chloramphenicol; D008628:Mercury
Auswirkungen unerwarteter Arzneiwirkungen ausgehend von den Contergan-Beobachtungen des Kinderklinikers.